View Future GrowthBeroni Group 과거 순이익 실적과거 기준 점검 0/6Beroni Group 의 수입은 연평균 -25.1%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 33.8%의 비율로 증가했습니다. 매출은 연평균 37.8%의 비율로 감소해 왔습니다.핵심 정보-25.08%순이익 성장률-17.81%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률-37.83%자기자본이익률-330.17%순이익률-3,539.94%최근 순이익 업데이트30 Jun 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 01Beroni Group Limited, Annual General Meeting, May 29, 2026Beroni Group Limited, Annual General Meeting, May 29, 2026. Location: at level 16, 175 pitt street, sydney nsw 2000 australia Australia공시 • Aug 30Beroni Group Limited, Annual General Meeting, Oct 01, 2024Beroni Group Limited, Annual General Meeting, Oct 01, 2024. Location: level 16, 175 pitt street, 2000 australia, sydney nsw Australia공시 • Jun 02Beroni Group Limited Announces That It Has Received Notification from Its European Authorized RepresentativeBeroni Group Limited announced that it has received notification from its European Authorized Representative, CMC Medical Devices & Drugs SL, that its latest enhanced COVID-19 Antigen Rapid Test Kit - Colloidal Gold Method (“Rapid Test Kit”) has complied with the applicable essential requirements of the council directive 98/79/EEC in vitro diagnostics as amended. Since its launch in 2020, the Rapid Test Kit has been further optimized and upgraded with greatly improved performance indicators. The enhanced Rapid Test Kit is not only simple and convenient to use but also is further improved with faster detection time and higher level of accuracy.공시 • Apr 01Beroni Group Limited Appoints John Chiplin to the Board of DirectorsBeroni Group Limited announced that it has appointed Dr. John Chiplin as an independent director to Beroni’s Board of Directors effective April 1, 2022. Dr. Chiplin is an accomplished biotech executive and investor with a proven track record of building successful biotech companies. Dr. John Chiplin, PhD is Managing Director of Newstar Ventures Ltd. and Chairman of the Board of Biotherapy Services, N4 Pharma plc and Scancell Holdings plc. Dr. Chiplin has significant operational, investment and international experience in the life science and technology industries. From 2014 to 2016, he served as executive director of Benitec Biopharma Inc. and helped executed the company’s US IPO.공시 • Sep 10Beroni Group Receives Approval for 43.5% R&D Rebate from Australian Government for the Novel, Potential Anti-Cancer Drug PENAOBeroni Group announced that PENAO Pty Ltd, its majority-owned, Sydney-based anti-cancer drug development company, has been approved by the Australian government for the annual 43.5% R&D rebate of eligible expenditure. The approval also includes R&D overseas activities so long as the total overseas expenditure claim over the life of the R&D activities is less than the expected total expenditure on the Australian R&D activities to which they are scientifically linked. The PENAO drug manufacture is expected to complete in the first half of 2022. Raw materials have been procured, familiarization studies have been completed and optimization work is progressing well at Aurigene Pharmaceutical Services Ltd, India.공시 • Sep 02Beroni Group Announces the Latest Clinical Study of its SARS-CoV-2 Antigen Test KitBeroni Group Limited announced the latest clinical study of its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) demonstrated an overall sensitivity of 95% and specificity of 100%. The clinical study was conducted with 70 subjects providing 105 true-positive specimens and 105 true-negative specimens. The results for the different types of swab sampling are as follows: Nasal sampling - sensitivity 92%; specificity 100%; Nasopharyngeal sampling - sensitivity 97%; specificity 100%; Oropharyngeal sampling - sensitivity 95%; specificity 100%. Beroni Group’s SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) received CE certification in December 2020 and was granted authorization for export in April 2021. The product can be used for in vitro qualitative auxiliary detection of SARS-CoV-2 antigen specimens and is for professional use only.공시 • May 29Beroni Group Limited announced that it has received $2 million in fundingBeroni Group Limited (NSX:BTG) announced a private placement of 20,000 convertible notes at a price of $100 per note for gross proceeds of $2,000,000 on May 28, 2021. The transaction included participation from an investor in Japan. The notes are zero coupon notes with a maturity date of May 27, 2022 and are convertible into common shares at a conversion price of $10. The number of shares to be issued in respect of each convertible note will be calculated by dividing the face value of the notes by the conversion price. Some or all of the convertible notes can be converted at the election of the noteholder at any time prior to maturity. The notes are issued at par.공시 • Apr 29Beroni Group’s SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) Has Received Export PermitBeroni Group Limited announced that it has received the notification that its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) is granted authorization for export. This test kit requires no blood, and only a nasopharyngeal swab is needed to collect samples. It can also deliver the test results within 10 minutes. Based on clinical tests, the sensitivity, specificity and total coincidence rate of anterior nasal sampling are 95.90%, 99.19% and 97.55% respectively, while the sensitivity, specificity and total coincidence rate of nasopharyngeal and oropharyngeal sampling are 98.36%, 99.19% and 98.78% respectively.매출 및 비용 세부 내역Beroni Group가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:BNIG.F 매출, 비용 및 순이익 (AUD Millions)날짜매출순이익일반관리비연구개발비30 Jun 251-1819031 Mar 250-1416031 Dec 240-1112030 Sep 240-88030 Jun 240-65031 Mar 240-86031 Dec 230-97030 Sep 231-98030 Jun 231-89031 Mar 231-89031 Dec 221-89030 Sep 221-68030 Jun 222-46031 Mar 222-46031 Dec 212-35030 Jun 212-34031 Mar 212-45031 Dec 202-56030 Jun 201-89031 Mar 202-89031 Dec 192-89030 Sep 192-68030 Jun 192-56031 Mar 192-35031 Dec 182-25030 Sep 182-25030 Jun 182-25031 Mar 182-24031 Dec 172-13030 Sep 17303030 Jun 17303031 Mar 17402031 Dec 16402031 Dec 15101031 Dec 140000양질의 수익: BNIG.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: BNIG.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: BNIG.F은 수익성이 없으며 지난 5년 동안 손실이 연평균 25.1% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 BNIG.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: BNIG.F은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(43%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: BNIG.F는 현재 수익성이 없으므로 자본 수익률이 음수(-330.17%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/10/14 19:36종가2025/07/17 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Beroni Group Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • May 01Beroni Group Limited, Annual General Meeting, May 29, 2026Beroni Group Limited, Annual General Meeting, May 29, 2026. Location: at level 16, 175 pitt street, sydney nsw 2000 australia Australia
공시 • Aug 30Beroni Group Limited, Annual General Meeting, Oct 01, 2024Beroni Group Limited, Annual General Meeting, Oct 01, 2024. Location: level 16, 175 pitt street, 2000 australia, sydney nsw Australia
공시 • Jun 02Beroni Group Limited Announces That It Has Received Notification from Its European Authorized RepresentativeBeroni Group Limited announced that it has received notification from its European Authorized Representative, CMC Medical Devices & Drugs SL, that its latest enhanced COVID-19 Antigen Rapid Test Kit - Colloidal Gold Method (“Rapid Test Kit”) has complied with the applicable essential requirements of the council directive 98/79/EEC in vitro diagnostics as amended. Since its launch in 2020, the Rapid Test Kit has been further optimized and upgraded with greatly improved performance indicators. The enhanced Rapid Test Kit is not only simple and convenient to use but also is further improved with faster detection time and higher level of accuracy.
공시 • Apr 01Beroni Group Limited Appoints John Chiplin to the Board of DirectorsBeroni Group Limited announced that it has appointed Dr. John Chiplin as an independent director to Beroni’s Board of Directors effective April 1, 2022. Dr. Chiplin is an accomplished biotech executive and investor with a proven track record of building successful biotech companies. Dr. John Chiplin, PhD is Managing Director of Newstar Ventures Ltd. and Chairman of the Board of Biotherapy Services, N4 Pharma plc and Scancell Holdings plc. Dr. Chiplin has significant operational, investment and international experience in the life science and technology industries. From 2014 to 2016, he served as executive director of Benitec Biopharma Inc. and helped executed the company’s US IPO.
공시 • Sep 10Beroni Group Receives Approval for 43.5% R&D Rebate from Australian Government for the Novel, Potential Anti-Cancer Drug PENAOBeroni Group announced that PENAO Pty Ltd, its majority-owned, Sydney-based anti-cancer drug development company, has been approved by the Australian government for the annual 43.5% R&D rebate of eligible expenditure. The approval also includes R&D overseas activities so long as the total overseas expenditure claim over the life of the R&D activities is less than the expected total expenditure on the Australian R&D activities to which they are scientifically linked. The PENAO drug manufacture is expected to complete in the first half of 2022. Raw materials have been procured, familiarization studies have been completed and optimization work is progressing well at Aurigene Pharmaceutical Services Ltd, India.
공시 • Sep 02Beroni Group Announces the Latest Clinical Study of its SARS-CoV-2 Antigen Test KitBeroni Group Limited announced the latest clinical study of its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) demonstrated an overall sensitivity of 95% and specificity of 100%. The clinical study was conducted with 70 subjects providing 105 true-positive specimens and 105 true-negative specimens. The results for the different types of swab sampling are as follows: Nasal sampling - sensitivity 92%; specificity 100%; Nasopharyngeal sampling - sensitivity 97%; specificity 100%; Oropharyngeal sampling - sensitivity 95%; specificity 100%. Beroni Group’s SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) received CE certification in December 2020 and was granted authorization for export in April 2021. The product can be used for in vitro qualitative auxiliary detection of SARS-CoV-2 antigen specimens and is for professional use only.
공시 • May 29Beroni Group Limited announced that it has received $2 million in fundingBeroni Group Limited (NSX:BTG) announced a private placement of 20,000 convertible notes at a price of $100 per note for gross proceeds of $2,000,000 on May 28, 2021. The transaction included participation from an investor in Japan. The notes are zero coupon notes with a maturity date of May 27, 2022 and are convertible into common shares at a conversion price of $10. The number of shares to be issued in respect of each convertible note will be calculated by dividing the face value of the notes by the conversion price. Some or all of the convertible notes can be converted at the election of the noteholder at any time prior to maturity. The notes are issued at par.
공시 • Apr 29Beroni Group’s SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) Has Received Export PermitBeroni Group Limited announced that it has received the notification that its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) is granted authorization for export. This test kit requires no blood, and only a nasopharyngeal swab is needed to collect samples. It can also deliver the test results within 10 minutes. Based on clinical tests, the sensitivity, specificity and total coincidence rate of anterior nasal sampling are 95.90%, 99.19% and 97.55% respectively, while the sensitivity, specificity and total coincidence rate of nasopharyngeal and oropharyngeal sampling are 98.36%, 99.19% and 98.78% respectively.